Justin Zamirowski - May 27, 2022 Form 4 Insider Report for Better Therapeutics, Inc. (BTTX)

Role
Chief Commercial Officer
Signature
/s/ Mark Heinen, Attorney-in-Fact
Stock symbol
BTTX
Transactions as of
May 27, 2022
Transactions value $
$839
Form type
4
Date filed
6/1/2022, 04:47 PM
Previous filing
May 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTTX Common Stock Options Exercise $839 +1.68K +4.76% $0.50 36.9K May 27, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTTX Stock Option (Right to Buy) Options Exercise $0 -1.68K -3.7% $0.00 43.6K May 27, 2022 Common Stock 1.68K $0.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Justin Zamirowski is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The Assumed Option (as defined in the Agreement and Plan of Merger, dated April 6, 2021, as amended, by and among Mountain Crest Acquisition Corp. II, MCAD Merger Sub Inc. and Better Therapeutics, Inc.) vests as to 1/4th of the shares subject to the Assumed Option on July 27, 2021 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The Assumed Option was granted on August 14, 2020.